RVMD

Revolution Medicines, Inc.

$182.15

+2.35% 2026-10-19

Healthcare

1M 3M 6M 1Y 2Y

RVMDSPY

-6.1%

-4.6%

+1.0%

+24.6%

YTD

+128.7%

+236.7%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$39.0B

P/E (trailing)–

P/E (forward)-31.3

52-week range52.48 – 224.31

Revenue growth (YoY, latest qtr)–

Dividend yield0.00%

Analyst consensusStrong Buy (24)

Mean price target$257.84 (+42%)

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

▼Piotroski F-score2/9

▲Altman Z12.1 (safe)

▲Analyst target+42% (24 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.40 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-5.83 vs trailing $-8.87. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

–

Operating margin

–

FCF margin

–

Net margin

–

Return on equity

-67.8%

Return on invested capital

–

Net debt / EBITDA

–

Current ratio

11.4×

Interest cover

-27.4×

Cash conversion (OCF/NI)

–

Piotroski F-score 2/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved

Altman Z-score 12.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$258

+42%

Analysts

Strong Buy

Range

$179–$320

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$0	$-1.1B	$-913.7M
2024	$0	$-600.1M	$-567.7M
2023	$11.6M	$-436.4M	$-358.3M
2022	$35.4M	$-248.7M	$-235.2M
2021	$29.4M	$-187.1M	$-153.7M
2020	$43.0M	$-108.2M	$-103.0M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: 2026-11-04 · during market · EPS est -2.39

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-05	-2.06	-3.06	-48.8%
2026-05-06	-1.84	-2.29	-24.6%
2026-02-25	-1.56	-1.86	-18.9%
2025-11-05	-1.41	-1.61	-14.3%
2025-08-06	-1.12	-1.31	-16.7%
2025-05-07	-1.06	-1.13	-7.0%
2025-02-26	-0.96	-1.12	-16.1%
2024-11-06	-0.88	-0.94	-7.0%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$0	–
2026-03-31	$0	–
2025-12-31	$0	–
2025-09-30	$0	–
2025-06-30	$0	–

Analyst actions

Truist Securities

2026-10-19 · main

Buy → Buy
PT $241

William Blair

2026-10-16 · init

→ Outperform

Needham

2026-10-15 · reit

Buy → Buy
PT $275

RBC Capital

2026-10-14 · main

Outperform → Outperform
PT $260

RBC Capital

2026-10-08 · main

Outperform → Outperform
PT $259

Truist Securities

2026-10-07 · main

Buy → Buy
PT $240